

This is a countywide group covering NHS Derby & Derbyshire Integrated Care Board, Derbyshire Community Health Service Foundation Trust, Derbyshire Healthcare Foundation Trust, University Hospital of Derby and Burton and Chesterfield Royal Hospital foundation trusts. It provides recommendations on the prescribing and commissioning of drugs
See <http://www.derbyshiremedicinesmanagement.nhs.uk/home>

Key Messages from July's JAPC meeting

Childrens referral guideline for Sub-Lingual Immuno Therapy (SLIT) – Grass pollen extract (Grazax) and House Dust Mite (HDM) extract (Acarizax) – updated to include second SLIT therapy – Acarizax (house dust mite extract), for use by paediatric specialists only. Beclometasone and budesonide nasal sprays have been removed from the guidance due to higher bioavailability and therefore less suitable for use in children.

Primary care management of irritable bowel syndrome guideline updated for a further 3 years with no significant changes.

High-Cost Drugs for secondary care, ICB commissioned:

- **Romosozumab for Severe Osteoporosis**, new commissioning algorithm based on NICE TA791 and NOGG/ROS statement. Treatment is currently licenced for people after menopause for 12 months duration only.
- **Filgotinib for moderate to severely active ulcerative colitis**, commissioning algorithm updated to include filgotinib as per NICE TA792 as a further treatment option.
- **Faricimab for treating diabetic macular oedema**, commissioning algorithm update to include faricimab (NICE TA799) as a 1st line treatment option alongside ranibizumab and aflibercept.
- **Faricimab for treating wet age-related macular degeneration**, commissioning algorithm update to include faricimab (NICE TA800) as a 1st line treatment option alongside ranibizumab and aflibercept.

Management of Emergency Contraception

Update of existing guideline in consultation with Sexual Health and Public Health specialists. Updated information includes urine pregnancy test 21 days after last episode of unprotected sexual intercourse, see guidance for full details; guidance included on the specific situation where an established combined hormonal contraception (CHC) user restarts CHC after a hormone-free interval and then misses 2-7 pills in the first week of pill-taking. Emerres replaces Levonelle as cost effective brand for levonorgestrel-emergency contraception.

Glaucoma guideline

The glaucoma guideline has been updated to include NICE NG81 recommendation on use of 360° selective laser trabeculoplasty (SLT) rather than eye drops for people newly diagnosed with chronic open angle glaucoma and ocular hypertension. The increased use of SLT should reduce the use of eye drops and potentially decrease the need for some patients to undergo cataract or intraocular pressure lowering surgery. Formulary changes included- Latanoprost as first line prostaglandin analogue (PGA), betaxolol 1st line beta blocker (BB), Eyzeetan replaces Ganfort as alternative PF PGA+BB and Cosopt PF now has generic version which is cheaper.

MHRA NOTICES

Metformin and reduced vitamin B12 levels: new monitoring advice for patients at risk. Decreased vitamin B12 levels, or vitamin B12 deficiency, is now considered to be a common side effect in patients on metformin treatment, especially in those receiving a higher dose or longer treatment duration and in those with existing risk factors. The MHRA are therefore advising checking vitamin B12 serum levels in patients being treated with metformin who have symptoms suggestive of vitamin B12 deficiency. They also advise that periodic monitoring for patients with risk factors for vitamin B12 deficiency should be considered. Type2 diabetes guideline/ endocrine formulary chapter updated with message. [Roche Accu-Chek Insight insulin pump with NovoRapid PumpCart insulin cartridges:](#) alert following cases of insulin leakage. The MHRA have issued a National Patient Safety Alert following serious reports of harm associated with insulin leakage during use of the Accu-Chek Insight Insulin pump with NovoRapid PumpCart prefilled insulin cartridges. Patients should be moved onto alternative insulin therapy where possible.

Guideline Group key messages – traffic light amendments

Dienogest – RED. For endometriosis as agreed by UHDB DTC. Specialists use only to allow clinicians to gain experience
Cinacalcet – RED for secondary hyperparathyroidism; noting **GREEN** specialist initiation for primary hyperparathyroidism from previous JAPC decision. **Sodium bicarbonate - GREEN** specialist recommendation 500mg capsules are the preferred cost-effective preparation. **RED** - sodium bicarbonate gastro-resistant caps (Nephrotrans). Nephrotrans is licensed for the treatment and maintenance against recurrence of metabolic acidosis and used for limited patients who cannot tolerate other sodium bicarbonate preparations due to gastric side effects.
Utrogestan vaginal capsules (micronised progesterone) - GREEN consultant/ specialist initiation. For prevention of miscarriage as per NICE NG126 (off-label). GP may continue until 16 completed weeks of pregnancy. Avoid use in patients with peanut allergy.
Humulin R500 – RED. Unlicensed in U.K. and not routinely available in primary care. Reserved for those with high insulin resistance not responding well to alternative high strength insulins.
Ethinylestradiol + etonogestrel vaginal ring - GREEN consultant/ specialist initiation. Brands include NuvaRing and SyreniRing. **Co-careldopa - GREEN** consultant/ specialist recommendation. Sinemet removed as cost-effective brand. Vagirux replaces Vagifem as preferred cost-effective brand for estradiol vaginal tablets. Norimin (CHC) removed from formulary as alternatives available. Solifenacin replaces oxybutynin as 1st line antimuscarinic for urinary frequency. Add in clarification- SLS regulations still apply to Viagra brand and all other PDE5 inhibitors (branded and generic) for the treatment of ED. ALL male patients are entitled to NHS treatment for erectile dysfunction with generic sildenafil but only those with certain conditions are entitled to NHS treatment with any of the other treatments including tadalafil. Cinacalcet for primary hyperparathyroidism- clarify when GP would consider repeating test following abnormal calcium level.
Thrush oral treatment in babies and lactating women- clarithromycin added as additional option to erythromycin, as per NICE/PHE Antimicrobial prescribing guidelines, following agreement with infant feeding lead DHcFT. Lipid non-FH- Clarify 'CKD' within the treatment flowchart as per NICE CG181 recommendation - Do not use a risk assessment tool to assess CVD risk in people with an eGFR<60 ml/min/1.73 m² and/or albuminuria.

Traffic light changes

Drug	Date considered	Decision	Details
Latanoprost	July 22	GREEN	1 st line prostaglandin analogue
Betaxolol	July 22	GREEN	1 st line beta blocker
Bimatoprost +timolol PF (Eyzetan)	July 22	GREY after con/spec initiation	Once daily, 2 nd line prostaglandin/beta blocker combination preparation.
Acarizax – house dust mite extract	July 22	RED	For use in specialist paediatric clinic only, in accordance with local protocol. See JAPC SLIT guidance
Romosozumab	July 22	RED	NICE TA791 - Romosozumab for treating severe osteoporosis. ICB commissioned
Filgotinib	July 22	RED	NICE TA792 - Filgotinib for treating moderately to severely active ulcerative colitis. ICB commissioned
Anifrolumab	July 22	DNP	NICE TA793 - Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)
Diroximel fumarate	July 22	RED	NICE TA794 - Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NHSE commissioned
Ibrutinib	July 22	DNP	NICE TA795 - Ibrutinib for treating Waldenstrom's macroglobulinaemia. NHSE commissioned
Venetoclax	July 22	RED	NICE TA796 - Venetoclax for treating chronic lymphocytic leukaemia. NHSE commissioned
Enfortumab vedotin	July 22	DNP	NICE TA797 - Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NHSE commissioned
Durvalumab	July 22	RED	NICE TA798 - Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NHSE commissioned
Faricimab	July 22	RED	NICE TA799 - Faricimab for treating diabetic macular oedema. ICB commissioned NICE TA800 - Faricimab for treating wet age-related macular degeneration. ICB commissioned
Pembrolizumab	July 22	RED	NICE TA801 - Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NHSE commissioned
Cemiplimab	July 22	RED	NICE TA802 - Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NHSE commissioned
Teduglutide	July 22	RED	NICE TA804 - Teduglutide for treating short bowel syndrome. NHSE commissioned
Zanubrutinib	July 22	RED	Zanubrutinib for treating Waldenstrom's macroglobulinaemia. NHSE commissioned. NHSE commissioned
Dapagliflozin	July 22	GREY	Use in adults and children aged ≥10 years for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance, or in addition to other medicinal products for the treatment of type 2 diabetes [Licence change to include children >10 years]
Macimorelin (Ghryvelin)	July 22	DNP	60mg granules for oral suspension in sachet. Diagnosis of growth hormone deficiency in adults. ICB commissioned
Netilmicin (Nettacin)	July 22	DNP	3mg in 1mL eye drops in single dose container. Topical treatment of external infections of the eye and its adnexa caused by netilmicin sensitive bacteria. ICB commissioned
Netilmicin + dexamethasone (Netildex)	July 22	DNP	3mg/1mg in 1mL eye drops in single-dose container. Treatment of inflammatory ocular conditions of the anterior segment of the eye, including post-operative cases, where bacterial infection or a risk of bacterial infection with netilmicin-susceptible microorganisms exists. ICB commissioned
Difelikefalin (Kapruvia)	July 22	RED	Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis. NHSE commissioned

DERBYSHIRE MEDICINES MANAGEMENT, PRESCRIBING AND GUIDELINES WEBSITE

This website is the first port of call for information on local NHS decisions and guidance on medicines use. It includes local prescribing formularies, JAPC decisions, traffic lights, shared care guidelines, medicines guidelines, newsletters, controlled drug resources, and other medicines management resources. The site improves upon previous sites in several ways. It is faster, more reliable, has its own search engine, and it is easier to find information. Content is constantly being updated and you can sign up for e-mail alerts to keep you up to date.

Definitions:

RED: drugs are those where prescribing responsibility lies with a hospital consultant or a specialist.

AMBER: drugs are those that although usually initiated within a hospital setting, could appropriately become the responsibility of the GP, under a shared care agreement.

GREEN*: drugs are regarded as suitable for primary care prescribing.

GREY*: drugs are those that JAPC does not recommend for use, except in exceptional circumstances, due to lack of data on safety, effectiveness, and/or cost-effectiveness.

Do Not Prescribe (DNP)*: drugs, treatments or medical devices are **not** recommended or commissioned* (*unless agreed through the individual funding request route)

CONSULTANT/SPECIALIST INITIATION: consultant/specialist issues the first prescription usually following a consultation because:

- a. The patient requires specialist assessment before starting treatment and/ or
- b. Specialist short term assessment of the response to the drug is necessary.

GPs will be asked to continue prescribing when the patient is stable or predictably stable

CONSULTANT/SPECIALIST RECOMMENDATION: consultant/specialist requests GPs prescribe initial and on-going prescriptions, but ensures:

- a. There is no immediate need for the treatment and is line with discharge policies and
- b. The patient response to the treatment is predictable and safe